The efficacy of teriparatide (Cinnopar®) on bone repair in mandibular fractures: A single blinded randomized clinical trial

J Craniomaxillofac Surg. 2022 Dec;50(12):923-928. doi: 10.1016/j.jcms.2022.12.002. Epub 2023 Jan 5.

Abstract

This study focused on the effects of teriparatide (CinnoPar) on healing and postoperative complications in mandibular bone fractures. In this single-blind randomized controlled trial, 30 patients with a mandibular fracture hospitalized for open reduction internal fixation were randomly assigned to the intervention (I) (n = 15) and control (C) (n = 15) groups. Both groups received daily acetaminophen and cephalexin for 1 week. For 1 month, Group I received daily subcutaneous teriparatide injections. The Radiographic Union Scale of the Mandible (RUSM) was used to assess mandibular bone fusion subjectively, and the Hounsfield unit (HU) was used to objectively assess radiodensity in a computed tomography (CT) scan. In both groups, the visual analog scale (VAS) score was used to assess postoperative complications such as pain, swelling, wound opening, pus secretion, and bitter taste. There was no significant difference in bone repair between the two groups in this study (P > 0.05). Teriparatide also had no effect on the postoperative complication rate in the control group (P > 0.05). Within the limitations of the study it seems that in mandibular fractures, teriparatide did not affect bone fusion or postoperative complications, so its use is not recommended for better bone fusion and fewer postoperative complications of mandibular fracture during the first month.

Keywords: Bone fusion; Bone repair; Cinnopar; Mandibular fractures; Teriparatide.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Bone Density Conservation Agents* / pharmacology
  • Bone Density Conservation Agents* / therapeutic use
  • Humans
  • Mandibular Fractures* / diagnostic imaging
  • Mandibular Fractures* / drug therapy
  • Mandibular Fractures* / surgery
  • Postoperative Complications / prevention & control
  • Single-Blind Method
  • Teriparatide / therapeutic use

Substances

  • Teriparatide
  • Bone Density Conservation Agents